Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elvucitabine
- Development stage
- Phase 2
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elvucitabine is an investigational nucleoside reverse transcriptase inhibitor (NRTI) developed for the treatment of HIV infection. It is a cytidine analog that inhibits HIV-1 reverse transcriptase by competing with natural substrates and causing chain termination during viral DNA synthesis. Elvucitabine was designed to have activity against both wild-type and certain drug-resistant strains of HIV. The drug was developed by Achillion Pharmaceuticals and has undergone clinical trials for use in combination antiretroviral therapy regimens.
- Other names
- 2',3'-dideoxy-2',3'-didehydro-beta-L-5-fluorocytidine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on elvucitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elvucitabine.